{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:19:30Z","timestamp":1788326370521,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":1076,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jmoldx.2016.08.006","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T02:15:16Z","timestamp":1479176116000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Fabrice","family":"Usseglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Raynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2016.08.006_bib1","series-title":"WHO Classification of Tumours of Haematopoetic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib7","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2005-03-1287","article-title":"On the molecular origins of the chronic myeloproliferative disorders: it all makes sense","volume":"105","author":"Kaushansky","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2009.07.002","article-title":"Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation","volume":"408","author":"Er","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2407-13-206","article-title":"Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection","volume":"13","author":"Zapparoli","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCPFHUQZ9AGUEKA","article-title":"Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods","volume":"132","author":"Cankovic","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"132","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib16","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Broseus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3343\/alm.2015.35.1.22","article-title":"Calreticulin exon 9 mutations in myeloproliferative neoplasms","volume":"35","author":"Ha","year":"2015","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4274\/tjh.2015.0220","article-title":"The mutation profile of calreticulin in patients with myeloproliferative neoplasms and acute leukemia","volume":"33","author":"Wang","year":"2016","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib20","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chaligne","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib21","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ajh.22058","article-title":"Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib24","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1038\/bcj.2015.21","article-title":"Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis","volume":"5","author":"Lim","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3109\/10428194.2015.1091932","article-title":"Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2 allelic burden","volume":"57","author":"Nussenzveig","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2010.034793","article-title":"Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms","volume":"96","author":"Pietra","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib27","doi-asserted-by":"crossref","first-page":"e8893","DOI":"10.1371\/journal.pone.0008893","article-title":"Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients","volume":"5","author":"Ugo","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jmoldx.2016.08.006_bib28","doi-asserted-by":"crossref","first-page":"e94554","DOI":"10.1371\/journal.pone.0094554","article-title":"Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing","volume":"9","author":"Bodian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib30","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib31","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5045\/br.2013.48.2.128","article-title":"The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm","volume":"48","author":"Park","year":"2013","journal-title":"Blood Res"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijlh.12404","article-title":"Real-time PCR and droplet digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"37","author":"Fontanelli","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/PAI.0000000000000228","article-title":"Is low positive JAK2 V617F mutation test result clinically significant?: multi-institutional study","volume":"24","author":"Wu","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmoldx.2016.08.006_bib38","first-page":"191","article-title":"JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm","volume":"36","author":"Liu","year":"2015","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157816301891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157816301891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T12:47:29Z","timestamp":1576241249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157816301891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1525157816301891"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2016.08.006","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2016.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}